awakn life sciences

Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway

Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic Expansion

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is pleased to announce the closing of its acquisition of Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in Norway, as previously announced on September 16, 2021. Upon the completion of the transaction, Axon will be renamed 'Awakn Clinics Oslo AS,' and Dr. Lowan Stewart will be appointed as Regional Director for the Nordics and Managing Director Awakn Clinics Oslo AS.

Awakn Clinics Oslo AS Clinic will serve as the Nordic hub from which Awakn plans to expand its clinical network across the region. The acquisition is part of Awakn's larger strategy to open several addiction and mental health clinics across Europe, including two clinics in the U.K., Bristol and London, that Awakn anticipates being operational this year. Awakn Clinics Oslo AS, led by Dr. Stewart, will be focused on delivering ketamine-assisted psychotherapy for patients and eventually will incorporate ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention, validated in a phase II ab clinical trial led by the University of Exeter and licensed by Awakn on March 2, 2021.

"The close of our acquisition in Norway is a key strategic milestone in making psychedelic therapeutics to treat addiction a mainstream treatment - helping individuals and their families to move past their addictions and live a fuller life," said Anthony Tennyson, Awakn's CEO. "This acquisition will enable Awakn to demonstrate the depth of our three-pronged revenue generation strategy: clinics in the U.K. and Europe, licensing partnership beyond the U.K. and Europe, and therapeutics commercialization. We look forward to opening more clinics across the Nordic region and globally as we aim to become the leading authority in the development and delivery of psychedelic therapeutics."

Pursuant to the terms of the transaction, Awakn has issued to the shareholders of Axon an aggregate of 200,000 common shares of Awakn at a deemed price of CAD$2.50. The initial 200,000 common shares issued are subject to a lock-up resulting in 10% having been released immediately on closing of the acquisition and 15% to be released every three months thereafter. Awakn has also agreed to pay to the shareholders of Axon the following additional consideration (the "Additional Consideration") of up CAD$1.35m based on Axon meeting certain milestones:

  • Opening a second clinic in Norway.
  • Opening a first clinic in a second Nordic country.
  • Opening a first clinic in a third Nordic country.
  • Achieving agreed revenue and EBIDTA targets.

Awakn shall have the option to pay any amount of the Additional Consideration in cash or common shares at its option. The value to calculate the number of the common shares to be issued shall be the greater of (i) a 10-day volume weighted average price, (ii) the minimum price allowable by the NEO Exchange, and (iii) CAD$2.50.

About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver this evidence backed psychedelic therapies in clinics in the U.K. and Europe and through licensing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to , the intended business of the Company, the expansion of the Company's business, and generation of revenue. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/98561

News Provided by Newsfile via QuoteMedia

The Conversation (0)

Right Season is Unaware of Any Material Change

(TheNewswire)

Right Season Investments Corp.

May 28, 2025 TheNewswire - Vancouver, British Columbia Right Season Investments Corp. (TSXV: LITT ), (" Right Season " or the " Company "). At the request of the Canadian Investment Regulatory Organization, the Company wishes to confirm that its management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

CSE Bulletin: Delist - Better Plant Sciences Inc.

The common shares of Better Plant Sciences Inc. will be delisted from the CSE at market close today, May 27, 2025.

Better Plant Sciences is currently suspended. See Bulletin 2024-0121.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Highlights:

  • 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June
  • Phase 3 COMP006 in TRD on track for 26-week data second half of 2026
  • Cash position of $260.1 million at March 31, 2025
  • Conference call on May 8 at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States.

HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of health, including the coordination of an integrated outpatient mental health and addictions health clinic. HealthPort has been operating facility, residential, and mobile based interventions of care in the lower Eastern Shore of Maryland for the past 45 years.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×